Search Results

FACT-LCS Functional Assessment of Cancer Therapy - Lung Cancer Subscale For patients with Lung cancer; a FACT-Lung Symptom Index (a subset of FACT-L containing 7 items) LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The FACT-LCS is the lung cancer subscale of the FACT-L. The Functional Assessment of Cancer Therapy-Lung (FACT-L) is a 36-item self-report instrument that measures multidimensional quality of life. It was developed from 1987-1993 and first published in 1995. The FACT-L meets a growing need for disease-specific health-related quality of life (HRQOL) questionnaires that address the general and unique concerns of patients diagnosed with lung cancer. Subsequent to its development, its results have been published in over 25 papers from over 15 unique data sets including over 4,000 people with lung cancer. Since 1995, studied groups have included cancer patients receiving chemotherapy, cancer patients receiving radiotherapy, terminally-ill patients and disease-free survivors. It is a widely-used, reliable and valid measure of multidimensional health status among people with lung cancer. It is brief, has clearly-written, easy-to-read questions, flexible modes of administration shown to be equivalent, and is translated in several dozen languages. MEASURE NAME: Functional Assessment of Cancer Therapy - Lung Cancer Subscale (FACT-LCS) VERSION: 4 NUMBER OF ITEMS: 7 PATIENT POPULATION: Lung cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Lung cancer symptom index TIME FOR COMPLETION: Less than 5 minutes SCORING: Manual scoring template, some items are reverse scored. Total scores available. RELATED MEASURES: FLSI , NFLSI-17 , FLSI-12 , FACT-PSI , FACT-L DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the FACT-LCS can be obtained by registering for permission. Users are not permitted to translate the FACT-LCS without permission from FACIT.org. Permission from FACIT.org to translate the FACT-LCS may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cheng, C., Chen, L., Ning, Z., Zhang, C., Chen, H., Chen, Z. Zhu, X., Xie, J. Acupuncture for cancer-related fatigue in lung cancer patients: a randomized, double blind, placebo-controlled pilot trial. Support Care Cancer 2017; 25(12): 3807-3814. doi: 10.1007/s00520-017-3812-7. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FLSI Functional Assessment of Cancer Therapy Lung Cancer Symptom Index - 6 Item Version LEARN MORE NFLSI-17 Functional Assessment of Cancer Therapy Lung Cancer Symptom Index - 17 Item Version LEARN MORE FLSI-12 Functional Assessment of Cancer Therapy Lung Cancer Symptom Index - 12 Item Version LEARN MORE

View all available languages for this measure. BACK FHSI Languages Arabic Chinese - Simplified Dutch English French German Hebrew Hungarian Italian Japanese Korean Russian Spanish Thai

Download this measure in English. BACK FACT-CTCL English Downloads Download PDF Download DOC

View all available languages for this measure. BACK FACIT-Pal-14 Languages Bengali Burmese Chinese - Simplified Chinese – Traditional Dutch English Farsi German Greek Hindi Indonesian Japanese Malay Malayalam Portuguese Sinhala Spanish Swahili Tagalog Tamil Telugu Thai Turkish Vietnamese

NFBSI-16 National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Breast Cancer Symptom Index - 16 Item Version For patients with Breast cancer; a FACT/NCCN-Breast Symptom Index LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview The NCCN/FACT Breast Cancer Symptom Index-16 contains cancer–related symptoms and concerns endorsed as high priority by both oncology patients and clinicians. Input on the most important symptoms to monitor during treatment for stage III or IV breast cancer was obtained from 52 patients recruited from National Comprehensive Cancer Network institutions as well as support service organizations. Participating patients shared their top-priority symptoms/concerns through open-ended interviews and symptom checklists. To ensure adequate content coverage, results were evaluated alongside the original version of the FBSI, which was created on the basis of a survey of oncology clinicians at National Comprehensive Cancer Network institutions and items in the FACIT measurement system. In put was also obtained from 10 National Comprehensive Cancer Network oncologists regarding whether symptoms were primarily related to disease or treatment. Results provided support for the NFBSI-16’s internal consistency reliability (α = 0.87) and validity as evidenced by moderate-to strong relationships with expected criteria. MEASURE NAME: National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Breast Cancer Symptom Index - 16 Item Version (NFBSI-16) VERSION: 2 NUMBER OF ITEMS: 16 PATIENT POPULATION: Breast cancer patients 18 years and older RECALL PERIOD: Past 7 days RESPONSE SCALE: 5 point Likert-type scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Disease-Related Symptoms – Physical, Disease-Related Symptoms – Emotional, Treatment Side-Effects, Function/Well-Being TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template, some items are reverse scored. Subscale scores and total scores possible. RELATED MEASURES: FACT-B , FBSI , FACT-G DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the NFBSI-16 can be obtained by registering for permission. Users are not permitted to translate the NFBSI-16 without permission from FACIT.org. Permission from FACIT.org to translate the NFBSI-16 may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Cella, D., Paul, D., Yount, S., Winn, R., Chang, C-H, Banik, D., & Weeks, J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Investigation 2003; 21(4): 526-535. doi: 10.108/CNV-120022366. Cella, D., Rosenbloom, S., Beaumont, J., Yount, J., Paul, D., Hampton, D., Abernethy, A., Jacobsen, P., Syrjala, K., & Von Roenn, J. Development and validation of 11 symptom indexes to evaluate response to chemotherapy for advanced cancer. Journal of the National Comprehensive Cancer Network; 2011; 9(3): 268-278. doi: 10.6004/jnccn.2011.0026. Clarke, N., Wong, B., Lawrance, R. et al. Validity, reliability, responsiveness, and clinically meaningful change threshold estimates of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16). J Patient Rep Outcomes 8, 97 (2024). https://doi.org/10.1186/s41687-024-00776-y Garcia, S., Rosenbloom, S., Beaumont, J., Merkel, D., Von Roenn, J., Rao, D., & Cella, D. Priority Symptoms in Advanced Breast Cancer: Development and Initial Validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16). Value in Health 2012; 15(1): 183-190. doi: 10.1016/j.jval.2011.08.1739. Rosenbloom, S., Yount, S., Yost, K., Hampton, D., Paul, D., Abernethy, A., Jacobsen, P., Syrjala, K., Von Roenn, J., Cella, D. Development and validation of eleven symptom indices to evaluate response to chemotherapy for advanced cancer: Measurement compliance with regulatory demands. Farquhar, I., Summers, K., Sorkin, A. (Eds.). The Value of Innovation: Impacts on Health, Life Quality and Regulatory Research. Emerald Group Publishing Inc. 2007; 16: 53-66. doi: 10.1016/S0194-3960(08)16003-6. Bonomi, A.E., Cella, D.D., Hahn, E.A., Bjordal, K., Sperner, B., Gangeri, L., Bergman, B., Willems, J., Hanquet, P., & Zittoun, R. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Quality of Life Research 1996; 5: 309-320. Eremenco, S., Arnold, B., Cella, D. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & the Health Professions 2005; 28(2): 212-232. Webster K., Cella D., Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Properties applications, and interpretation. Health and Quality of Life Outcomes 2003; 1(1): 79-85. Yost K.J., Eton D.T. Combining distribution- and anchor-based approaches to determine minimally important differences: The FACIT experience. Evaluation & the Health Professions 2005; 28(2): 172-191. LICENSE THIS MEASURE Related Measures Related Measures FACT-B Functional Assessment of Cancer Therapy – Breast LEARN MORE FBSI FACT Breast Symptom Index LEARN MORE FACT-G Functional Assessment of Cancer Therapy – General LEARN MORE

View all available languages for this measure. BACK FACIT-CNI-NTX Languages Chinese - Simplified Czech English French Hindi Italian Portuguese Punjabi Spanish

Download this measure in English. BACK FACT-AntiA English Downloads Download PDF Download DOC

DMD Diarrhoea Management Diary For patients with metastatic breast cancer LICENSE THIS MEASURE Overview Language Availability Licensing Selected References Related Measures Overview Overview Below are the details for the DMD measure: MEASURE NAME: Diarrhoea Management Diary (DMD) VERSION: 9 NUMBER OF ITEMS: 8 PATIENT POPULATION: Metastatic breast cancer patients 18 and older experiencing diarrhoea RECALL PERIOD: Past 7 days RESPONSE SCALE: 4 point scale DATA COLLECTION: Paper and electronic ADMINISTRATION: Self-administration and interview when applicable SUBSCALE DOMAINS: Not available TIME FOR COMPLETION: 5-10 minutes SCORING: Manual scoring template RELATED MEASURES: FACIT-AD , NVMBQ , FACIT-D DOWNLOAD MEASURE IN ENGLISH DOWNLOAD SCORING DOCUMENT Language Availability Available translations of the DMD can be obtained by registering for permission. Users are not permitted to translate the DMD without permission from FACIT.org. Permission from FACIT.org to translate the DMD may also be contingent upon timeline expectations and availability of FACIT staff. Translations must undergo a rigorous methodology under the guidance of FACIT.org which includes multiple translators, QA steps and cognitive interviews with patients. For commercial use, FACITtrans is the approved translation vendor to translate the FACIT measurement system. Please contact us for more information. VIEW AVAILABLE LANGUAGES Language Availability Licensing Licensing Licensing fees are assessed on a per trial/per measure basis for commercial use. There is no fee for use of the English version, but a license should be obtained. Non-commercial use is assessed on a case-by-case basis. Licensing fees are typically not applied to investigator-initiated research, students, or clinical use. To license an available version of this measure for commercial or non-commercial use, please complete our registration form . All of the information provided in the form will be kept strictly confidential. For questions, please contact us . LICENSE THIS MEASURE Selected References Selected References Harder H, Shilling VM, May SF, Cella D, Schmid P, Fallowfield LJ. The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer. Breast Cancer Res Treat . 2020 Oct;183(3):629-638. doi: 10.1007/s10549-020-05798-w. Epub 2020 Jul 27. PMID: 32720113; PMCID: PMC7497672. Abdullah M, Firmansyah M. Clinical Approach and Management of Chronic Diarrhea. Acta Med Indones 2013; 45:157-65. Atherton P, Halyard M, Sloan J, et al. Assessment of patient-reported measures of bowel function before and after pelvic radiotherapy: an ancillary study of the North Central Cancer Treatment Group study N00CA. Support Care Cancer , 2013; 21:1193-9. Benson A III, Ajani J, Catalano R, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004; 22:2918–26. Cherny N. Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review. Pain Symptom Manage 2008; 36:413-23. Clark J, Talcott J. Symptom indexes to assess outcomes of treatment for early prostate cancer. Med Care 2001; 39:1118-30. Davidson-Homewood J, Norman A, Kūlchler T, et al. Development of a disease specific questionnaire to supplement a generic tool for QOL in colorectal cancer. Psycho-Oncol 2003; 12:675-85. Haddock M, Sloan J, Bollinger J, et al. Patient Assessment of Bowel Function During and After Pelvic Radiotherapy: Results of a Prospective Phase III North Central Cancer Treatment Group Clinical Trial. J Clin Oncol 2007;25:1255-9. O'Cathain A, Thomas K. "Any other comments?" Open questions on questionnaires – a bane or a bonus to research? BMC Medical Research Methodology 2004; 4:25. Stein A. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2010; 2:51-63. Temple L, Bacik J, Savatta S, et al. The Development of a Validated Instrument to Evaluate Bowel Function After Sphincter-Preserving Surgery for Rectal Cancer. Dis Colon Rectum 2005;48:1353-65. Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes 2003; 1:79. Wild D, Grove A, Martin M, et al. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translating adaptation. Value Health 2005; 2:94-104. LICENSE THIS MEASURE Related Measures Related Measures FACIT-AD Functional Assessment of Chronic Illness Therapy - Abdominal Discomfort LEARN MORE NVMBQ Nausea and Vomiting Management Barriers Questionnaire LEARN MORE FACIT-D Functional Assessment of Chronic Illness Therapy - Diarrhea LEARN MORE

Download scoring documents for this measure. BACK FACT-An Scoring Downloads Download DOC

Download this measure in English. BACK PROMIS Item Bank v1.0 Dyspnea Functional Limitations English Downloads Download PDF Download DOC

Download this measure in English. BACK FACT-G7 English Downloads Download PDF Download DOC

Download this measure in English. BACK COST English Downloads Download PDF Download DOC